Cover Image

New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants

Aim. To search for new pharmacogenetic biomarkers of bleeding risk in patients taking rivaroxaban and dabigatran for different indications: atrial fibrillation, endoprosthesis of large joints of lower limbs.Material and methods. The study enrolled 29 patients (17 patients received dabigatran and 12...

Full description

Saved in:

Bibliographic Details
Main Authors:	K. B. Mirzaev (Author), D. V. Ivashchenko (Author), I. V. Volodin (Author), E. A. Grishina (Author), K. A. Akmalova (Author), A. A. Kachanova (Author), A. I. Skripka (Author), R. M. Minnigulov (Author), T. E. Morozova (Author), O. A. Baturina (Author), A. N. Levanov (Author), T. V. Shelekhova (Author), A. I. Kalinkin (Author), D. A. Napalkov (Author), A. A. Sokolova (Author), D. A. Andreev (Author), I. N. Sychev (Author), P. O. Bochkov (Author), D. A. Sychev (Author)
Format:	Book
Published:	Столичная издательская компания, 2020-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

IMPACT OF ABCB1 AND CES1 GENETIC POLYMORPHISMS ON TROUGH STEADY-STATE DABIGATRAN CONCENTRATIONS IN PATIENTS AFTER ENDOPROSTHESIS OF KNIFE JOIN
by: D. A. Sychev, et al.
Published: (2018)

MicroRNAs as Novel Biomarkers for P2Y12 – Inhibitors Resistance Prediction
by: Rytkin E, et al.
Published: (2021)

Effect of CYP3A4/5, ABCB1 gene polymorphisms on the residual equilibrium concentration of apixaban and bleeding in patients with non-valvular atrial fibrillation and deep vein thrombosis
by: l. V. Fedina, et al.
Published: (2024)

The CES1 Gene rs2244613 Minor Allele Impact on the Safety Profile of Dabigatran Etexilate: Meta-Analysis
by: S. P. Abdullaev, et al.
Published: (2020)

Clinical Signs and Medical History as Predictors of Enalapril-Associated Dry Cough in Cardiovascular Patients
by: I. V. Sychev, et al.
Published: (2023)

EVALUATION OF PLATELET AGGREGATION IN CLINICAL PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015)

EVALUATION OF PLATELET AGGREGATION IN CLINICAL PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015)

Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis
by: L. V. Fedina, et al.
Published: (2023)

Associations of CYP2D6, ABCB1 2677G>T/A and 3435C>T with effectiveness and safety of pharmacotherapy for acute psychotic episodes in adolescents over 28 days
by: D. V. Ivaschenko, et al.
Published: (2021)

Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population
by: K. B. Mirzaev, et al.
Published: (2019)

Patients' Pharmacogenetic Characteristics and the Risk of Adverse Reactions to Non-steroidal Anti-inflammatory Drugs: Case Reports
by: A. S. Zhiryakova, et al.
Published: (2024)

Study of the Effect of Polymorphic Markers of the NAT2 Gene on the Risk of Adverse Drug Reactions in Patients with Pulmonary Tuberculosis Who Received Isoniazid and Rifampicin
by: A. A. Kachanova, et al.
Published: (2021)

THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015)

THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015)

Current and future use of vitamin D<sub>3</sub> in patients with COVID-19
by: I. N. Sychev, et al.
Published: (2020)

Analysis of associations between pharmacodynamic genetic factors and antipsychotics' effectiveness and safety in adolescents with acute psychotic episodes taking antipsychotics during a 28-day follow-up
by: D. V. Ivaschenko, et al.
Published: (2021)

New Possibilities in Quantitative Assessment of Albuminuria in Patients with Atrial Fibrillation and Chronic Kidney Disease
by: A. A. Sokolova, et al.
Published: (2021)

Laboratory predictors of clinical outcomes in patients with atrial fibrillation
by: A. A. Sokolova, et al.
Published: (2021)

INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
by: K. B. Mirzaev, et al.
Published: (2015)

INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
by: K. B. Mirzaev, et al.
Published: (2015)

Current and future use of umifenovir in patients with COVID-19
by: Yu. Yu. Kiselev, et al.
Published: (2020)

Dexamethasone use in patients with COVID-19
by: V. A. Otdelenov, et al.
Published: (2020)

Could canakinumab be used for COVID-19?
by: V. A. Otdelenov, et al.
Published: (2020)

Possibility to use direct oral anticoagulants to prevent thromboembolic events in patients with COVID-19
by: V. A. Otdelenov, et al.
Published: (2020)

Comparative placebo-controlled study on the effect of dietary supplements containing omega-3 polyunsaturated fatty acids on hemodynamics and lipid metabolism in postmenopausal women
by: D. A. Napalkov, et al.
Published: (2024)

NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME
by: K. B. Mirzaev, et al.
Published: (2018)

CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban
by: Sychev DA, et al.
Published: (2020)

Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease
by: N. A. Shatalova, et al.
Published: (2023)

Current and future use of dipyridamole in patients with COVID-19
by: I. S. Burashnikova, et al.
Published: (2020)

Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis
by: V. M. Tsvetov, et al.
Published: (2020)

Change of opinion on the use of hydroxychloroquine for COVID-19 treatment and prevention
by: K. B. Mirzaev, et al.
Published: (2020)

Thrombodynamics Test in Assessing the Risk of Thrombus Formation in Patients with Atrial Fibrillation Taking Direct Oral Anticoagulants
by: Z. A. Gebekova, et al.
Published: (2022)

Possibility for the use of bromhexine to prevent infection with SARS-CoV-2
by: K. A. Zagorodnikova, et al.
Published: (2020)

Current and future use of remdesivir in patients with COVID-19
by: V. M. Tsvetov, et al.
Published: (2020)

Is it possible to use riamilovir to prevent infection and treat COVID-19?
by: V. M. Tsvetov, et al.
Published: (2020)

Model for predicting risk of developing drug-induced liver injury during remdesivir therapy: observational prospective open case-control study
by: Yu. V. Shevchuk, et al.
Published: (2023)

Rationale for use mefloquine for COVID-19 treatment
by: V. A. Otdelenov, et al.
Published: (2020)

THE PHARMACOKINETICS OF APIXABAN IN PATIENTS WITH CARDIOEMBOLIC STROKE IN ACUTE PHASE
by: A. V. Kryukov, et al.
Published: (2016)

Evaluation of the Influence of <i>CYP2C9* 2, CYP2C9*3</i> Gene Polymorphisms on the Efficacy and Safety of Postoperative Analgesia with Ketoprofen in Patients after Cardiac Surgery
by: T. E. Morozova, et al.
Published: (2021)

The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty [Corrigendum]
by: Sychev DA, et al.
Published: (2018)